The CyberKnife Robotic Radiosurgery System deployed at the CHUM

NewsGuard 100/100 Score

In operation since recently at the Centre hospitalier de l'Université de Montréal (CHUM), the CyberKnife(R) Robotic Radiosurgery System, is revolutionizing the treatment of both cancerous and non-cancerous tumors anywhere in the body. Used in radiation oncology, the CyberKnife System is the latest word in radiosurgery technology. Designed to destroy tumours using radiation beams, it is the first system of its kind to treat tumors non-invasively to be installed in Canada. It provides a pain-free, non-surgical option for patients who have inoperable or surgically complex tumors, or who may be looking for an alternative to surgery.

Though its name may conjure images of scalpels and surgery, the CyberKnife treatment involves no cutting. Accuray's CyberKnife System uses stereotactic radiotherapy to treat tumours. One of the most remarkable aspects of the CyberKnife is its ability to track tumour movement as the patient breathes. Its unequalled precision means that the CyberKnife does not require the use of rigid head-frames that are screwed into the patient' skull to minimize any movement, such as in the case of brain tumour treatment. The CyberKnife uses two x-ray cameras installed on the ceiling for continuous image guidance.

"With precision that enables high doses of radiation to be channelled to a hair's-breadth, the CyberKnife reduces the time of treatment needed in most cases," adds Dr. Jean-Paul Bahary, chief of the Radio-oncology Department of the CHUM, and associate professor, Université de Montréal.

The CHUM will use the CyberKnife mainly in the treatment of intracranial tumours, spinal tumours, certain types of lung, urological, gastrointestinal, and otorhinolaryngological cancers, and for research.

Source:

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Immunotherapy breakthrough: Pembrolizumab extends time to recurrence in aggressive bladder cancer